Form 4: Annexon CEO Douglas Love Granted 1.25M Stock Options

Annexon Inc.'s President and CEO, Douglas Love, was granted 1,250,000 stock options with an exercise price of $5.10, vesting over four years.

Summary

• Douglas Love, President and CEO of Annexon, Inc. (ANNX), was granted 1,250,000 stock options.
• The options have an exercise price of $5.10 per share.
• The earliest transaction date for this grant is February 19, 2026.
• The options begin vesting on February 19, 2026, with 1/48th of the shares vesting on each monthly anniversary.
• The options will be fully vested and exercisable on the fourth anniversary of the vesting commencement date (February 19, 2030).
• The expiration date for these stock options is February 19, 2036.
• The grant is subject to Mr. Love's continuous service with Annexon, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the grant of a significant number of stock options to the CEO aligns management's long-term interests with shareholder value creation, contingent on future stock price appreciation.

Positives

• The grant of a significant number of stock options to the CEO aligns management's long-term interests with shareholder value, as the options become valuable only if the stock price appreciates.
• This compensation structure incentivizes the CEO to drive company growth and performance over a multi-year period.

Negatives

• The future exercise of these options could lead to dilution for existing shareholders, increasing the total number of outstanding shares.

Risks

• Potential future dilution of existing shareholders if the 1,250,000 stock options are exercised.
• The value of the options is contingent on the company's stock price performance, which is subject to market and operational risks.

Future Outlook

The grant of these long-term stock options suggests an expectation of future growth and increased shareholder value by the company's board and management, as the options' value is tied to the future appreciation of Annexon's stock price.

Industry Context

StockSavvy.ai notes that granting stock options to executive leadership is a common practice in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align executive interests with those of shareholders. The vesting schedule over four years is also standard for such grants.

Comparison to Industry Standards

• The grant of 1,250,000 stock options to a CEO is a substantial award, typical for a company of Annexon's stage and market capitalization, particularly in the biotech sector where long-term drug development cycles necessitate sustained executive commitment.
• The exercise price of $5.10, likely the market price on the grant date, is standard practice to ensure the options have intrinsic value only upon future stock price appreciation, similar to grants at comparable biotech firms like BioNTech or Moderna during their growth phases.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased management incentive to drive stock price appreciation.
• Employees: No direct impact mentioned, but a strong executive incentive structure can indirectly benefit overall company performance and employee morale.

Next Steps

• The stock options will vest monthly over the next four years, commencing February 19, 2026.
• Douglas Love may exercise the vested options at any time before the expiration date of February 19, 2036, subject to his continuous service with the Issuer.

Key Dates

Keywords

Annexon, ANNX, stock options, executive compensation, insider transaction, CEO, Douglas Love, Form 4